Skip to main content
Virtual Visits

Video visit appointments available 7 days a week from 9:00am to 11:00pm. Learn More

COVID-19 Updates

COVID-19 Updates: Get the latest on vaccine information, in-person appointments, video visits and more. Learn More

Our Researchers

Director

Dr. Leonid Metelitsa’s research focuses on understanding the role of Vα24-invariant natural killer T (NKT) cells in tumor immunity and translating this knowledge into NKT cell-based cancer immunotherapies. His group was the first to demonstrate that NKT cells localize to primary tumors in human patients and that presence of these cells at the tumor site is associated with favorable outcomes in the clinic (Metelitsa et al., JEM, 2004).

Phone
832-824-4395

AICT Faculty

Amy Courtney's main focus in the lab is to examine the impact of natural killer T cells (NKTs) on the neuroblastoma microenvironment.  In particular, she is interested in the cross-talk between NKTs and immunosuppressive tumor-associated macrophages (TAMs), which have been shown to correlate with both metastatic disease and poor outcome in neuroblastoma patients. Her work has determined that human NKTs directly target TAMs in both a contact-dependent and -independent manner.

Phone
832-824-4290

Dr. Andras Heczey's research focuses on developing novel treatments for children with solid tumors by redirecting the immune system to attack and kill cancer cells by using genetically-engineered T cells and Natural Killer T cells.

Phone
832-822-4242

Dr. Leonid Metelitsa’s research focuses on understanding the role of Vα24-invariant natural killer T (NKT) cells in tumor immunity and translating this knowledge into NKT cell-based cancer immunotherapies. His group was the first to demonstrate that NKT cells localize to primary tumors in human patients and that presence of these cells at the tumor site is associated with favorable outcomes in the clinic (Metelitsa et al., JEM, 2004).

Phone
832-824-4395

Dr. Xin Xu is a formally-trained microbiologist with extensive experience in translational research. His postdoctoral research focused on development of an innovative salmonella-based cancer vaccine platform that is currently being submitted as the subject of an Investigational New Drug (IND) application with the goal of clinical evaluation.

Phone
832-824-4232